文献速递瓣膜外科

经导管与外科主动脉瓣置换术治疗单纯原生主动脉瓣反流的比较

Transcatheter vs Surgical Aortic Valve Replacement in Pure Native Aortic Regurgitation.
PubMed 文献 · Ann Thorac Surg · 2022-09-19

该回顾性队列研究纳入2016至2019年因单纯原生主动脉瓣反流接受择期经导管主动脉瓣置换术(TAVR)或外科主动脉瓣置换术(SAVR)的医疗保险受益人共11027例(TAVR 1147例,SAVR 9880例)。经过重叠倾向评分加权调整后,TAVR与SAVR的30天死亡率相当,但中位随访31个月时TAVR的全因死亡风险(HR 1.41)和再次主动脉瓣置换风险(HR 2.13)均高于SAVR。作者指出TAVR患者更年长、更衰弱,不能排除残余混杂对长期结果的影响。

要点

  • 在单纯原生主动脉瓣反流患者中,TAVR的调整30天死亡率与SAVR相当。
  • 中位随访31个月,TAVR的全因死亡风险高于SAVR(HR 1.41,95%CI 1.03-1.93,P=0.02)。
  • TAVR需再次主动脉瓣置换的风险高于SAVR(HR 2.13,95%CI 1.05-4.34,P=0.03)。

核心结论

  • 在单纯原生主动脉瓣反流的医疗保险患者中,使用当前市售经导管瓣膜的TAVR短期结果与SAVR相当。
  • 尽管TAVR的长期结果劣于SAVR,但鉴于TAVR患者更年长、更衰弱,不能排除残余混杂对长期结果的影响。

研究设计与样本

  • 回顾性队列研究,纳入2016至2019年因单纯原生主动脉瓣反流接受择期TAVR或SAVR的医疗保险受益人。
  • 排除合并主动脉瓣狭窄、接受瓣中瓣介入或同期二尖瓣或升主动脉手术的患者。
  • 共纳入11027例患者,其中TAVR组1147例,SAVR组9880例;采用重叠倾向评分加权调整混杂因素。

主要发现

  • TAVR组患者较SAVR组更年长、合并症更少、衰弱更轻。
  • TAVR与SAVR的调整30天死亡率相当。
  • 中位随访31个月(四分位距18-44个月),TAVR的全因死亡风险高于SAVR(HR 1.41,95%CI 1.03-1.93,P=0.02)。
  • TAVR需再次主动脉瓣置换的风险高于SAVR(HR 2.13,95%CI 1.05-4.34,P=0.03)。
  • TAVR的卒中风险(HR 1.65,95%CI 0.95-2.87,P=0.07)和感染性心内膜炎风险(HR 2.60,95%CI 0.92-7.36,P=0.07)在数值上高于SAVR,但未达统计学显著。

局限性

  • 作者指出,鉴于TAVR患者更年长、更衰弱,不能排除残余混杂对长期结果的影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Patients with pure native aortic regurgitation (AR) have been excluded from transcatheter aortic valve replacement (TAVR) trials. We sought to examine midterm outcomes with TAVR in AR compared with surgical AVR (SAVR) in a contemporary cohort. METHODS: Medicare beneficiaries who underwent elective TAVR or SAVR for pure AR from 2016 to 2019 were identified. Patients with concomitant aortic stenosis and who underwent a valve-in-valve intervention or concomitant mitral valve or ascending aorta operation were excluded. The primary outcome was all-cause mortality in the longest follow-up. Secondary outcomes included stroke, endocarditis, and redo AVR. Overlap propensity score weighting was used to adjust for confounders. RESULTS: During the study period, 11,027 patients with pure AR underwent elective AVR (TAVR, n = 1147; SAVR, n = 9880). SAVR patients were younger, with fewer comorbidities and less frailty compared with TAVR patients. TAVR was associated with adjusted 30-day mortality comparable to SAVR. After a median follow-up of 31 months (interquartile range, 18-44 months), TAVR was associated with higher adjusted risk of death (hazard ratio [HR], 1.41; 95% CI, 1.03-1.93; P = .02) and need for redo-AVR (HR, 2.13; 95% CI, 1.05-4.34; P = .03) compared with SAVR. The risk of stroke (HR, 1.65; 95% CI, 0.95-2.87; P = .07) and endocarditis (HR, 2.60; 95% CI, 0.92-7.36; P = .07) was numerically higher with TAVR. CONCLUSIONS: In Medicare patients with pure native AR, TAVR with the current commercially available transcatheter valves has comparable short-term outcomes. Although long-term outcomes were inferior to SAVR, the possibility of residual confounding, biasing long-term outcomes, given older and frailer TAVR patients, cannot be excluded.

来源:Ann Thorac Surg,查看原文。版权归原作者所有。

引用

  1. Mentias A, Saad M, Menon V, et al. Transcatheter vs Surgical Aortic Valve Replacement in Pure Native Aortic Regurgitation. Ann Thorac Surg. 2022. PMID: 36967709. doi:10.1016/j.athoracsur.2022.09.016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。